Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
| Study Number Sort descending | Lead Group | Study Title | CIRB | Study Status | |
|---|---|---|---|---|---|
| E4412 | ECOG-ACRIN | A Phase I Study with an Expansion Cohort/Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma | Adult CIRB - Late Phase Emphasis | Available to Open | |
| E4512 | ECOG | A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein | Adult CIRB - Late Phase Emphasis | Available to Open | |
| E4599 | ECOG | Randomized Phase II/III Trial of Paclitaxel plus Carboplatin With or Without Bevacizumab (NSC #704865) in Patients with Advanced Nonsquamous NSCLC | Adult CIRB - Late Phase Emphasis | Completed | |
| E4A03 | ECOG | A Randomized Phase III Study of CC-5013 Plus Dexamethasone Versus CC-5013 Plus Low Dose Dexamethasone in Multiple Myeloma with Thalidomide Plus Dexamethasone Salvage Therapy for Non-Responders | Adult CIRB - Late Phase Emphasis | Available to Open | |
| E4A08 | ECOG | A Randomized Phase III Trial of Melphalan and Dexamethasone (MDex) versus Bortezomib; Melphalan; and Dexamethasone (BMDex) for Untreated Patients with Systemic Light-chain (AL) Amyloidosis Ineligible for Autologous Stem-cell Transplantation | Adult CIRB - Late Phase Emphasis | Completed | |
| E5103 | ECOG | A Double-Blind Phase III Trial of Doxorubicin and Cyclophosphamide Followed by Paclitaxel with Bevacizumab or Placebo in Patients with Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer | Adult CIRB - Late Phase Emphasis | Available to Open | |
| E5202 | ECOG | A Randomized Phase III Study Comparing 5-FU; Leucovorin and Oxaliplatin Versus 5-FU; Leucovorin; Oxaliplatin and Bevacizumab in Patients with Stage II Colon Cancer at High Risk for Recurrence to Determine Prospectively the Prognostic Value of Molecular Markers | Adult CIRB - Late Phase Emphasis | Available to Open | |
| E5204 | ECOG | Intergroup Randomized Phase III Study of Postoperative Oxaliplatin; 5-Fluorouracil; and Leucovorin vs Oxaliplatin; 5-Fluorouracil; Leucovorin and Bevacizumab for Patients with Stage II or III Rectal Cancer Receiving Pre-Operative Chemoradiation | Adult CIRB - Late Phase Emphasis | Completed | |
| E5508 | ECOG | Randomized Phase III Study of Maintenance Therapy with Bevacizumab; Pemetrexed; or a Combination of Bevacizumab and Pemetrexed Following Carboplatin; Paclitaxel and Bevacizumab for Advanced Non-Squamous NSCLC | Adult CIRB - Late Phase Emphasis | Available to Open | |
| E6201 | ECOG | A Phase III; Randomized Study of Gemcitabine [fixed-dose rate infusion] and Oxaliplatin (NSC 266046) versus Gemcitabine [fixed-dose rate infusion] versus Gemcitabine [30-minute infusion] in Pancreatic Carcinoma | Adult CIRB - Late Phase Emphasis | Completed |